Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha, Hunan 410219, P.R. China.
Mol Med Rep. 2025 Jan;31(1). doi: 10.3892/mmr.2024.13387. Epub 2024 Nov 8.
Cataracts are primarily caused by aging or gene mutations and are the leading cause of blindness globally. As the older population increases, the number of patients with a cataract is expected to grow rapidly. At present, cataract surgery to replace the lens with an artificial intraocular lens is the principal treatment method. However, surgery has several drawbacks, including economic burdens and complications such as inflammation, xerophthalmia, macular edema and posterior capsular opacification. Thus, developing an effective non‑surgical treatment strategy is beneficial to both patients and public health. Mechanistically, cataract formation may be due to various reasons but is primarily initiated and promoted by oxidative stress and is closely associated with crystallin aggregation. In the present review, the current research progress on anti‑cataract drugs, including antioxidants and protein aggregation inhibitors is examined. It summarizes strategies for preventing and treating cataract through cell apoptosis and protein aggregation inhibition while discussing their limitations and further prospects.
白内障主要由衰老或基因突变引起,是全球致盲的主要原因。随着老年人口的增加,白内障患者的数量预计将迅速增加。目前,用人工晶状体替换晶状体的白内障手术是主要的治疗方法。然而,手术有几个缺点,包括经济负担和炎症、干眼症、黄斑水肿和后囊混浊等并发症。因此,开发有效的非手术治疗策略对患者和公共健康都有益。从机制上讲,白内障的形成可能有多种原因,但主要是由氧化应激引发和促进的,并且与晶状体蛋白聚集密切相关。在本综述中,检查了包括抗氧化剂和蛋白质聚集抑制剂在内的抗白内障药物的当前研究进展。它总结了通过细胞凋亡和蛋白质聚集抑制来预防和治疗白内障的策略,同时讨论了它们的局限性和进一步的前景。